Vaxcyte (PCVX)

• Market cap: $6.85B
• 1 day: -1.01%
• 5 days: -8.02%
• 1 month: -19.76%
• 3 months: -21.55%
• 6 months: -1.61%
• Year to date: 1.01%
• 1 year: 35.44%
• 5 years: 112.55%
• 10 years: 79.46%
• Sector: Healthcare
• Industry: Biotechnology

About: Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Employees: 507